ABBOTT PARK, Illinois, March 30, 2011 /PRNewswire/ -- Abbott announced today it enrolled the first patient in the CALM Study, a clinical trial with HUMIRA(R) (adalimumab), to determine if tailoring therapy to more stringent measures of disease activity in patients with early moderate to severe Crohn's disease will improve mucosal healing. The study will assess patients monitored with those stringent criteria over 56 weeks compared to patients monitored with less stringent and more commonly used clinical disease management criteria.

LUCERNE, Switzerland, March 30, 2011 /PRNewswire/ -- -- EF Education First's English Proficiency Index reveals wide gaps in English skills across the world --

EF Education First, the world leader in international education, today unveiled the first comprehensive index ranking the proficiency of English among a broad population in 44 countries and territories around the world where English is not the native language.

The EF English Proficiency Index (EF EPI) is the first index that compares the English ability of adults in different countries. The index uses a unique set of test data (see methodology) from over two million people across 44 countries who took free online English tests over three years (2007-2009).